Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.

@article{Buckner1989EvaluationOM,
  title={Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.},
  author={Jan C. Buckner and John H. Edmonson and James N. Ingle and Daniel J. Schaid},
  journal={American journal of clinical oncology},
  year={1989},
  volume={12 5},
  pages={384-6}
}
Menogaril, an anthracycline analog of nogalamycin, is reported to have greater cytotoxicity against certain malignant cell lines and less cardiotoxicity in rabbits than doxorubicin. To evaluate the possible therapeutic benefit of this drug, we studied menogaril in 21 patients with metastatic sarcomas who had received no prior chemotherapy. Menogaril was administered intravenously over 1 h every 3-4 weeks at a dose of 200 mg/m2 in 500 ml of 5% dextrose in water. One patient experienced a partial… CONTINUE READING